clinical research prime

Pediatric Phlebotomist

Intranasal RSV

  • 18 – 30 months of age.
  • A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine in RSV Seropositive Children.
  • Participants will receive study related treatment at no cost and will be compensated for time and travel.

Eligible participants must meet following criteria:

  • Child does not have a history of wheezing or receipt of bronchodilator therapy

  • No one in the household is pregnant

Maternal RSV

  • A Phase 3 study to investigate the safety, tolerability, and immunogenicity of revaccinating pregnant women during subsequent pregnancies.
  • Participants will receive study related prevention at no cost and will be compensated for time and travel.

Eligible participants must meet following criteria:

  • Must be currently pregnant

  • Cannot be first pregnancy

  • Must have confirmed receipt of a single dose of RSVpreF (Abrysvo) in previous pregnancy